Shares of Neoleukin Therapeutics, Inc. (NASDAQ:NLTX – Get Free Report) rose 8.3% on Thursday . The company traded as high as $10.71 and last traded at $10.46. Approximately 391,066 shares traded hands during mid-day trading, an increase of 681% from the average daily volume of 50,104 shares. The stock had previously closed at $9.66.
Neoleukin Therapeutics Price Performance
The stock has a fifty day moving average of $16.39 and a 200 day moving average of $27.89. The stock has a market cap of $82.61 million, a price-to-earnings ratio of -2.83 and a beta of 1.11.
About Neoleukin Therapeutics
Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma.
See Also
- Five stocks we like better than Neoleukin Therapeutics
- Investing In Preferred Stock vs. Common Stock
- Conagra Stock Could Thrive as Tariffs Hit Other Sectors
- How to Invest in Blue Chip Stocks
- Grocery Costs and Tariffs Now Top of Mind in Everyday Conversations, New Survey Finds
- How to Read Stock Charts for Beginners
- Spotify Stock Eyes Double-Digit Upside—Is Now the Time to Buy?
Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
